Announced Fri, 24 Jul · 13:48 IST
Q1 FY27 results: revenue up 19%, PAT up 27%, INR 5 dividend, 2 acquisitions
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.7%1-day move
₹1690.10
prior close
₹1689.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+0.4+1.1+0.7+7.7+6.8————————
Up moveDown movePending
AI summary
Dr. Lal PathLabs Q1 FY27 consolidated revenue INR 7,977M (up 19.1% YoY), net profit INR 1,705M (up 27.2% YoY), EPS INR 10.15. Board declared interim dividend of INR 5 per share, record date July 30, 2026. Acquired 100% stake in Shahbazkers Diagnostic for INR 200M. Approved 80% stake buy in Sunshine Healthcare Ghana (up to INR 380M) and 30% stake in Neuome Technologies (up to INR 35M). Also granted 119,300 stock options.
Likely market impact
Strong Q1 PAT growth of 27% YoY, interim dividend, plus acquisitions in India and Ghana signal healthy growth momentum.